caplacizumab caplacizumab caplacizumab (inn; trade name cablivi) is a bivalent single-domain antibody (vhh) designed for the treatment of thrombotic thrombocytopenic purpura (ttp) and thrombosis. caplacizumabmonoclonal antibodytypesingle domain antibodysourcehumanizedtargetvon willebrand factor (vwf)clinical datatrade namescabliviother namesalx-0081, caplacizumab-yhdpahfs/drugs.commonographmedlineplusa619030license data us dailymed: caplacizumab pregnancycategory au: b1 routes ofadministrationintravenous, subcutaneousatc codeb01ax07 (who) legal statuslegal status au: s4 (prescription only) ca: rx-only / schedule d uk: pom (prescription only) us: ℞-only eu: rx-only identifierscas number915810-67-2drugbankdb06081chemspidernoneunii2r27ab6766keggd11160chemical and physical dataformulac1213h1891n357o380s10molar mass27876.19 g·mol−1 this drug was developed by ablynx nv. on 30 august 2018, it was approved in the european union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (attp), in conjunction with plasma exchange and immunosuppression". it is an anti-von willebrand factor humanized immunoglobulin. it acts by blocking platelet aggregation to reduce organ injury due to ischemia. results of the phase ii titan trial have been reported. in february 2019, caplacizumab-yhdp (cablivi, ablynx nv) was approved in the united states for the treatment of adults with acquired thrombotic thrombocytopenic purpura (attp). the drug is used in combination with plasma exchange and immunosuppressive therapy. the u.s. food and drug administration (fda) considers it to be a first-in-class medication.